AKRON, OHIO (Dec. 21, 1:30 p.m. ET) — The Austen BioInnovation Institute in Akron and Lubrizol Corp. have teamed up to share resources in hopes of speeding the development and commercialization of new technologies.
The partnership will provide Lubrizol, a maker of specialty chemicals in Wickliffe, Ohio, the opportunity to collaborate on research with Austen and its stakeholders, which include Akron Children's Hospital, Akron General Health System, Northeast Ohio Medical University, Summa Health System and the University of Akron.
In return, Austen and its member organizations will have “access to the expertise of an innovative and diverse corporation that has a global footprint and a history of chemistry, engineered polymers and consumer specialty products advancements,” according to a news release.
Deb Langer, general manager of Lubrizol's life science polymers division, said the partnership will allow the company to “better understand a patient's needs in order to design and develop effective polymer solutions.”
Dr. Frank Douglas, Austen's president and CEO, said in a statement that the collaboration was an important moment for the region.
“It provides an opportunity to not only enhance new product development efforts in biomaterial applications in orthopedics and wound care, but also allows two Ohio-based entities to add to the regional and state economic capabilities and reach,” Dr. Douglas said.